Financings in Brief: Davinci Scientific Corporation
This article was originally published in The Gray Sheet
Davinci Scientific Corporation: Files registration statement for an initial public offering of 1.3 mil. units, each consisting of one common share and one four-year warrant to buy one common share. The company, formed in 1992, aims to acquire "emerging medical technologies and technology companies" whose products are cleared by FDA and protected by patents, but "have not been effectively marketed to the healthcare community." Davinci has acquired rights to one product, the Resusci-Cath minimally invasive arterial oxygen monitor. The firm also has owns 44% of cardiac monitoring manufacturer CardioDynamics and 5% of Vital Heart Systems, a developer of a non-invasive variance cardiography diagnostic product.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.